Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib plus hyper-CVAD/methotrexate-cytarabine for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
ACTRN12607000609459Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Haematological toxicity and Grade 3-4 non-haematological toxicities attributable to dasatinib. Started Nov 2008; status: completed.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ACTRN12607000609459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000609459.